News stories about Proteon Therapeutics (NASDAQ:PRTO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Proteon Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 46.2684107433727 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
PRTO has been the topic of several analyst reports. HC Wainwright set a $3.00 target price on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research report on Saturday, May 13th. Maxim Group set a $6.00 target price on shares of Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, Zacks Investment Research downgraded shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company’s stock. Proteon Therapeutics has an average rating of “Hold” and an average price target of $8.14.
Shares of Proteon Therapeutics (NASDAQ:PRTO) opened at 1.35 on Tuesday. The company’s 50-day moving average price is $1.37 and its 200-day moving average price is $1.57. The firm’s market capitalization is $22.64 million. Proteon Therapeutics has a 52-week low of $1.10 and a 52-week high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.04. On average, equities research analysts expect that Proteon Therapeutics will post ($1.65) EPS for the current fiscal year.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
